Abstract：
OBJECTIVE: To study the effects of delaying pegfilgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival.
METHODS: Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC.
RESULTS: The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p = 0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p = 0.28) as well as a trend towards longer median survival (16 months versus 19 months, p = 0.69) and overall survival (21 months versus 31 months, p = 0.47).
CONCLUSIONS: A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients.
METHODS: Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC.
RESULTS: The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p = 0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p = 0.28) as well as a trend towards longer median survival (16 months versus 19 months, p = 0.69) and overall survival (21 months versus 31 months, p = 0.47).
CONCLUSIONS: A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients.
摘要：
目的：为了研究AML患者大剂量阿糖胞苷（HiDAC）巩固后延迟pegfilgrastim给药的效果，感染并发症,和生存。
方法：单中心回顾性分析55例接受pegfilgrastim早期给药（72小时内）或延迟给药（72小时后）HiDAC的患者。
结果：中性粒细胞恢复时间在早期和延迟组之间的差异相似（18天对19天，p<0.28）。化疗后早期给药组中有四名患者感染，而延迟组中没有感染（p=0.04）。延迟给药组的发热性中性粒细胞减少率也有所下降(23.1%对10.3%,p=0.28)以及中位生存期更长的趋势(16个月对19个月，p=0.69）和总生存期（21个月对31个月，p=0.47）。
结论：在早期和延迟给药组之间没有观察到中性粒细胞恢复时间的差异，但感染并发症的减少可能支持在这些患者中延迟给药。
方法：单中心回顾性分析55例接受pegfilgrastim早期给药（72小时内）或延迟给药（72小时后）HiDAC的患者。
结果：中性粒细胞恢复时间在早期和延迟组之间的差异相似（18天对19天，p<0.28）。化疗后早期给药组中有四名患者感染，而延迟组中没有感染（p=0.04）。延迟给药组的发热性中性粒细胞减少率也有所下降(23.1%对10.3%,p=0.28)以及中位生存期更长的趋势(16个月对19个月，p=0.69）和总生存期（21个月对31个月，p=0.47）。
结论：在早期和延迟给药组之间没有观察到中性粒细胞恢复时间的差异，但感染并发症的减少可能支持在这些患者中延迟给药。
